Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Status: open17-073 - A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Treatment for Pediatric Skin Infection
Description
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
Sponsors
This trial is sponsored by Durata Therapeutics.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at 251-415-1598 or by email at marmistead@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
Sub Investigators
![Benjamin Estrada]()
View ProfileBenjamin Estrada, M.D.Pediatric Infectious DiseaseAssistant Dean for Educational Strategies and Faculty Development; Professor and Vice Chair of Pediatrics
